Wei Li
Impact in
- Cancer Research top 0.1%
- Breast Cancer Treatment Studies
- Cancer, Hypoxia, and Metabolism
- Oncology top 0.2%
- HER2/EGFR in Cancer Research
Papers in
- Cancer Research 123
- MicroRNA in disease regulation 42
- Oncology 167
- HER2/EGFR in Cancer Research 36
- Co-authors
- Duane D. Miller (97 shared papers)Andrzej T. Slominski (69 shared papers)Robert Charles Tuckey (55 shared papers)Tae‐Kang Kim (40 shared papers)Jianjun Chen (19 shared papers)Yan Lü (20 shared papers)Zorica Janjetović (33 shared papers)Jin Wang (21 shared papers)
- Journals
- Journal of Medicinal Chemistry (26 papers)Frontiers in Oncology (19 papers)Journal of Biological Chemistry (18 papers)PLoS ONE (18 papers)Bioorganic & Medicinal Chemistry Letters (16 papers)
- Partner nations
- ChinaUnited StatesAustralia
In The Last Decade
Wei Li
1.3k papers receiving 51.7k citations
Wei Li's Hit Papers
Peers
Comparison fields: 5 of 173
- Cancer Research 5.7k
- Oncology 7.4k
- Pulmonary and Respiratory Medicine 6.7k
- Pathology and Forensic Medicine 3.6k
- Molecular Biology 9.7k
Countries citing papers authored by Wei Li
This map shows the geographic impact of Wei Li's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Wei Li with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Wei Li more than expected).
Fields of papers citing papers by Wei Li
This network shows the impact of papers produced by Wei Li. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Wei Li. The network helps show where Wei Li may publish in the future.
Co-authors
The 25 scholars most cited alongside Wei Li, linked wherever they have co-authored with each other. Click a name or a connecting line to browse the papers they share.
All Works
Showing the 20 most-cited of 1.3k papers — load more, or switch the sort, to bring in the rest.
| # | Work | ||
|---|---|---|---|
| 1 | Olaparib for Metastatic Breast Cancer in Patients with a Germline BRCA Mutation Hit paper breakdown → | 2017 | 2591 |
| 2 | Trastuzumab Deruxtecan in Previously Treated HER2-Low Advanced Breast Cancer Hit paper breakdown → | 2022 | 1933 |
| 3 | Afatinib versus cisplatin plus gemcitabine for first-line treatment of Asian patients with advanced non-small-cell lung cancer harbouring EGFR mutations (LUX-Lung 6): an open-label, randomised phase 3 trial Hit paper breakdown → | 2014 | 1738 |
| 4 | HIF-1α pathway: role, regulation and intervention for cancer therapy Hit paper breakdown → | 2015 | 1572 |
| 5 | Pembrolizumab in combination with gemcitabine and cisplatin compared with gemcitabine and cisplatin alone for patients with advanced biliary tract cancer (KEYNOTE-966): a randomised, double-blind, placebo-controlled, phase 3 trial Hit paper breakdown → | 2023 | 728 |
| 6 | An Overview of Tubulin Inhibitors That Interact with the Colchicine Binding Site Hit paper breakdown → | 2012 | 666 |
| 7 | Trastuzumab deruxtecan versus trastuzumab emtansine in patients with HER2-positive metastatic breast cancer: updated results from DESTINY-Breast03, a randomised, open-label, phase 3 trial Hit paper breakdown → | 2022 | 482 |
| 8 | Gefitinib versus vinorelbine plus cisplatin as adjuvant treatment for stage II–IIIA (N1–N2) EGFR-mutant NSCLC (ADJUVANT/CTONG1104): a randomised, open-label, phase 3 study Hit paper breakdown → | 2017 | 427 |
| 9 | 2011 | 412 | |
| 10 | 2015 | 405 | |
| 11 | 2009 | 390 | |
| 12 | Overcoming Therapeutic Resistance in HER2-Positive Breast Cancers with CDK4/6 Inhibitors Hit paper breakdown → | 2016 | 382 |
| 13 | The BACE1 inhibitor verubecestat (MK-8931) reduces CNS β-amyloid in animal models and in Alzheimer’s disease patients Hit paper breakdown → | 2016 | 377 |
| 14 | Afatinib versus erlotinib as second-line treatment of patients with advanced squamous cell carcinoma of the lung (LUX-Lung 8): an open-label randomised controlled phase 3 trial Hit paper breakdown → | 2015 | 363 |
| 15 | 2017 | 356 | |
| 16 | 2009 | 347 | |
| 17 | Pyrotinib plus capecitabine versus lapatinib plus capecitabine for the treatment of HER2-positive metastatic breast cancer (PHOEBE): a multicentre, open-label, randomised, controlled, phase 3 trial Hit paper breakdown → | 2021 | 324 |
| 18 | 2013 | 322 | |
| 19 | Discovery of Zanubrutinib (BGB-3111), a Novel, Potent, and Selective Covalent Inhibitor of Bruton’s Tyrosine Kinase Hit paper breakdown → | 2019 | 298 |
| 20 | 2009 | 279 |
About Wei Li
Wei Li is a scholar working on Cancer Research, Oncology, Pulmonary and Respiratory Medicine, Molecular Biology and Pathology and Forensic Medicine, having authored 1.3k papers that have together received 52.8k indexed citations. Recurring topics across this work include Synthesis and biological activity (71 papers), Lung Cancer Treatments and Mutations (62 papers), Vitamin D Research Studies (60 papers), MicroRNA in disease regulation (42 papers), Cell death mechanisms and regulation (40 papers), HER2/EGFR in Cancer Research (36 papers), Pharmacogenetics and Drug Metabolism (35 papers) and Nanoparticle-Based Drug Delivery (35 papers). The work is most often cited by research in Cancer Research (5.7k citations), Oncology (7.4k citations), Pulmonary and Respiratory Medicine (6.7k citations), Pathology and Forensic Medicine (3.6k citations) and Molecular Biology (9.7k citations). Wei Li has collaborated with scholars based in China, United States and Australia. Frequent co-authors include Duane D. Miller, Andrzej T. Slominski, Robert Charles Tuckey, Tae‐Kang Kim, Jianjun Chen, Yan Lü, Zorica Janjetović, Jin Wang, Kangcheng Ruan and Binghe Xu. Their work appears in journals such as Journal of Medicinal Chemistry, Frontiers in Oncology, Journal of Biological Chemistry, PLoS ONE and Bioorganic & Medicinal Chemistry Letters.
Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.